*ST交昂(600530.SH):產權交易所確認了公司與東軟載波簽訂的產權交易合同
格隆匯11月26日丨*ST交昂(600530.SH)公佈,之前公告披露,公司第七屆董事會第二十一次會議、2020年第一次臨時股東大會,審議通過了《關於出售資產的議案》,同意公司通過上海聯合產權交易所有限公司(“產權交易所”)公開掛牌競價轉讓公司和下屬全資子公司上海交大昂立生物製品銷售有限公司所持上海交大昂立生命科技發展有限公司(“生命科技公司”或“標的企業”)100%的股權。
公司於2020年10月14日至2020年11月10日通過產權交易所公開掛牌轉讓生命科技公司100%股權,掛牌期內,徵集到意向受讓方上海東軟載波微電子有限公司(“東軟載波”)。2020年11月25日,產權交易所確認了公司與東軟載波簽訂的《產權交易合同》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.